Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Assets (2022 - 2025)

Historic Assets for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $1.4 billion.

  • Indivior Pharmaceuticals' Assets fell 327.87% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 327.87%. This contributed to the annual value of $1.3 billion for FY2024, which is 2514.22% down from last year.
  • Indivior Pharmaceuticals' Assets amounted to $1.4 billion in Q3 2025, which was down 327.87% from $1.5 billion recorded in Q2 2025.
  • Indivior Pharmaceuticals' Assets' 5-year high stood at $1.9 billion during Q3 2023, with a 5-year trough of $1.3 billion in Q4 2024.
  • For the 5-year period, Indivior Pharmaceuticals' Assets averaged around $1.6 billion, with its median value being $1.5 billion (2024).
  • In the last 5 years, Indivior Pharmaceuticals' Assets tumbled by 62.18% in 2023 and then plummeted by 2514.22% in 2024.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Assets stood at $1.8 billion in 2021, then fell by 3.44% to $1.8 billion in 2022, then decreased by 0.62% to $1.8 billion in 2023, then dropped by 25.14% to $1.3 billion in 2024, then grew by 7.6% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.4 billion during Q1 2025.